Molecular characterization of primary and recurrent high grade serous ovarian cancer

Dan Cacsire Castillo-Tong
Translational Gynecology Group
Department of Obstetrics and Gynecology
Medical University of Vienna
OCTIPS
Ovarian Cancer Therapy – Innovative Models Prolong Survival (FP7 EU Project)
Duration: 4 years (01.01.2012 – 31.12.2015)
11 Partners
3 000 000 EURO
HGSOC (high grade serous ovarian cancer)
Working Hypotheses

Primary tumor -> Platinum-based therapy -> Resistant cells -> Relapsed tumor
Aims
HGSOC
(high grade serous ovarian cancer)

New therapeutic strategies

Surgery  Platinum-based chemotherapy  6 months

primary tumors

recurrent tumors

genome, mRNA, microRNA, functional molecules + pathways
resistance modeling
Two clusters of recurrent tumors

FC>5, AUROC>75%, 142 genes  
126/142 are immune related
Molecular difference between primary and recurrent HGSOC
Conclusion

• Molecular characterization of recurrent HGSOC together with their primary counterparts (66 patients)
• Therapeutic impact
• Establishment of research models for HGSOC (~40)

Perspective

• Immune therapies in HGSOC
• Therapies targeting tumor stroma
• Using cell line models to investigate new therapeutic strategies